Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
None USD 0.00(0%)
Last update at 2026-11-20T21:00:31.834736Z
Market Cap
0.00M

Momentum Score

…

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.37
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
34.07M
Revenue Per Share
22.03
Gross Profit TTM
0.00M
Debt / Equity
1.13
ROE
-140.43%
Net Debt
4.06M
ROCE
-227.36%
Diluted EPS TTM
-1.30

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -0.61M -37.66M -10.92M -10.95M
Net income -0.64M -37.71M -10.99M -10.98M
Selling general administrative 35.87M 37.21M 18.12M 28.70M
Selling and marketing expenses 0.73M - - -
Gross profit 13.49M 11.36M 9.78M 13.77M
Reconciled depreciation 1.17M 0.54M 0.56M 0.67M
Ebit -22.38M -25.85M -8.33M -14.92M
Ebitda -21.18M -25.16M -6.49M -8.75M
Depreciation and amortization 1.21M 0.69M 1.84M 6.17M
Operating income -22.38M -25.85M -8.33M -14.92M
Other operating expenses 51.05M 49.95M 27.18M 41.10M
Interest expense 0.20M 0.34M 2.90M 2.16M
Tax provision 0.03M 0.06M 0.06M 0.03M
Interest income 0.17M 0.02M 0.03M 0.03M
Net interest income -0.20M -0.34M -2.87M -2.13M
Income tax expense 0.03M 0.06M 0.06M 0.03M
Total revenue 28.67M 24.10M 18.85M 26.18M
Total operating expenses 35.87M 37.21M 18.12M 28.70M
Cost of revenue 15.19M 12.74M 9.07M 12.41M
Total other income expense net 21.77M -11.81M -2.59M 3.97M
Net income from continuing ops -0.64M -37.71M -10.99M -10.98M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 27.93M 50.88M 53.22M 24.14M 28.75M
Intangible assets 2.63M 3.03M 3.45M 3.87M 4.29M
Other current assets 5.58M 0.81M 4.99M 0.50M 0.19M
Total liab 23.14M 27.00M 41.88M 18.31M 58.93M
Total stockholder equity 4.79M 23.88M 11.34M 5.83M -30.18M
Other current liab 4.49M 12.18M 3.24M 4.24M 10.92M
Common stock 0.00M 0.03M 0.02M 0.01M -
Capital stock 0.00M 0.03M 0.02M 0.01M 0.00M
Retained earnings -99.65M -79.52M -78.88M -41.17M -30.18M
Other assets 0.00M - - - -
Cash 1.34M 17.21M 24.55M 8.08M 7.30M
Total current liabilities 18.09M 20.89M 13.84M 4.42M 11.74M
Current deferred revenue - 6.94M 3.24M - -
Net debt 4.06M -15.86M -24.55M -8.08M 30.90M
Short term debt 4.59M 0.50M 6.69M - -
Short long term debt 3.90M - - - -
Short long term debt total 5.40M 1.35M - - 38.20M
Other stockholder equity 104.44M 103.37M 90.20M 46.99M -
Total current assets 23.07M 43.14M 46.42M 19.58M 23.47M
Short term investments 0.08M 10.55M - - -
Net receivables 5.16M 7.41M 12.43M 3.29M 4.79M
Long term debt - - - - 38.20M
Inventory 10.91M 7.17M 4.46M 7.09M 10.48M
Accounts payable 9.01M 1.28M 0.66M 0.18M 0.82M
Non currrent assets other 0.28M 3.13M 3.08M 0.32M 0.49M
Non current assets total 4.86M 7.74M 6.80M 4.56M 5.28M
Capital lease obligations 1.50M 1.35M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -5.16M -0.01M 0.00M 25.39M
Total cash from financing activities 14.02M 43.19M 13.19M 16.40M
Net income -0.64M -37.71M -10.99M -10.98M
Change in cash -7.33M 16.46M 0.82M 4.12M
Begin period cash flow 24.74M 8.28M 7.45M 3.33M
End period cash flow 17.41M 24.74M 8.28M 7.45M
Total cash from operating activities -16.20M -26.71M -12.37M -37.68M
Issuance of capital stock 9.39M 29.94M - -
Depreciation 1.17M 0.54M 0.56M 0.67M
Change to inventory -2.81M 2.59M 2.98M -3.54M
Change to account receivables -0.07M -0.61M 1.17M -0.76M
Other cashflows from financing activities 4.63M 13.25M 13.19M 16.40M
Capital expenditures 0.04M 0.01M 0.00M 0.54M
Change in working capital 2.79M -1.50M -2.83M -23.94M
Stock based compensation 1.85M 0.13M - -
Other non cash items -21.37M -1.04M 0.88M -3.42M
Free cash flow -16.24M -26.73M -12.37M -38.22M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
MKKGY
Merck KGaA ADR
-0.68
2.09%
31.83 21.25 14.93 3.10 2.14
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
163.45 24.86 15.11 3.13 1.98
TAK
Takeda Pharmaceutical Co Ltd ADR
0.38
1.77%
21.79 - 10.96 0.01 1.20
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16

Profile*

Biofrontera Inc. Warrants

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

120 Presidential Way, Woburn, MA, United States, 01801

781-245-1325

83

Name Title Year Born
Dr. Hermann Luebbert Ph.D. CEO, President & Executive Chairman 1956
Mr. Eugene Frederick Leffler III Chief Financial Officer 1985
Ms. Erica F. Gates CPA, M.B.A. Senior Director of Finance & Principal Accounting Officer NA
Mr. Jon Lyons M.B.A., Ph.D. Vice President of Scientific & Medical Affairs NA
Ms. Alycia Torres Vice President of Administration NA
Mr. Daniel Hakansson J.D. General Counsel & Head of Compliance NA
Ms. Samantha Widdicombe Senior Director of Strategic Accounts & Communications NA
Mr. Mark Baldyga Vice President of Sales & Marketing NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…